Roivant Sciences (ROIV) Interest & Investment Income (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Interest & Investment Income came in at $136.9 million in Q4 2025, down 32.8% YoY from $203.8 million in Q4 2024, and up 5205.27% on a QoQ basis from $2.6 million in Q3 2025.
Roivant Sciences (ROIV) Interest & Investment Income (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Interest & Investment Income data on file, last reported at $136.9 million in Q4 2025.
- Quarterly Interest & Investment Income fell 32.8% year-over-year to $136.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $343.7 million (down 15.88% YoY) and the FY2026 annual result came in at $178.1 million, down 31.07% from the prior year.
- Interest & Investment Income improved to $136.9 million in Q4 2025, from $2.6 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $203.8 million in Q4 2024 to a low of $62000.0 in Q3 2021.
- A 5-year average of $43.2 million and a median of $15.5 million in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 9045.16% — and 2025, when it plunged 99.35%.
- Tracing ROIV's Interest & Investment Income over 5 years: stood at $199000.0 in 2021, then soared by 8894.97% to $17.9 million in 2022, then jumped by 251.77% to $63.0 million in 2023, then jumped by 223.58% to $203.8 million in 2024, then tumbled by 32.8% to $136.9 million in 2025.
- The last three Interest & Investment Income figures came in at $136.9 million (Q4 2025), $2.6 million (Q3 2025), and $470000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | 36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.92 Mn |
| Dec 31, 2025 | 136.93 Mn |
| Sep 30, 2025 | 2.58 Mn |
| Jun 30, 2025 | 470,000.00 |
| Dec 31, 2024 | 203.75 Mn |
| Sep 30, 2024 | 69.77 Mn |
| Jun 30, 2024 | 72.13 Mn |
| Dec 31, 2023 | 62.97 Mn |
| Sep 30, 2023 | 14.30 Mn |
| Jun 30, 2023 | 16.72 Mn |
| Dec 31, 2022 | 17.90 Mn |
| Sep 30, 2022 | 5.67 Mn |
| Jun 30, 2022 | 1.98 Mn |
| Dec 31, 2021 | 199,000.00 |
| Sep 30, 2021 | 62,000.00 |